Acquisitions and Divestitures - Consideration Paid For HRA Pharma (Details) $ in Millions, € in Billions	Apr. 29, 2022 USD ($)	Apr. 29, 2022 EUR (€)	Jul. 02, 2022 USD ($)	Dec. 31, 2021 USD ($)
Assets Acquired
Operating lease assets			$ 207.1	$ 166.9
Goodwill			$ 3,514.9	$ 2,999.4
HRA Pharma
Business Acquisition [Line Items]
Purchase Price	$ 1,945.6	€ 1.8
Assets Acquired
Cash and cash equivalents	44.1
Accounts receivable	78.1
Inventories	38.5
Prepaid expenses and other current assets	16.8
Property, plant and equipment, net	4.6
Operating lease assets	9.7
Goodwill	616.2
Indefinite lived intangibles	1,388.1
Deferred income taxes	11.2
Other non-current assets	0.8
Total assets	2,208.1
Liabilities assumed
Accounts payable	44.5
Deferred income taxes	16.1
Accrued customer programs	9.0
Other accrued liabilities	13.9
Deferred income taxes	168.8
Other non-current liabilities	10.1
Total liabilities	262.4
Noncontrolling interest	0.1
Net Assets Acquired	1,945.6
HRA Pharma | In-process research and development
Assets Acquired
Indefinite lived intangibles	63.3
HRA Pharma | Trademarks, trade names, and brands
Assets Acquired
Definite-lived intangible assets, net	1,072.3
HRA Pharma | Developed product technology
Assets Acquired
Definite-lived intangible assets, net	170.2
HRA Pharma | Distribution networks
Assets Acquired
Definite-lived intangible assets, net	$ 82.3